Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 5,056 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: PTSD, Alcohol Use Disorder
Interventions: Sertraline, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 21 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Male Participants
Interventions: AG-881, [13C315N3]AG-881; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Major Depression
Interventions: Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day, Placebo; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Healthy Subjects
Interventions: PF-06651600, midazolam, efavirenz; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Itraconazole, PKC412; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York

Conditions: Covid19
Interventions: Acebilustat, Camostat; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Pleasanton, California • Stanford, California

Conditions: Hypertension, Left Ventricular Hypertrophy, Overweight
Interventions: Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo, Losartan 50/100 mg placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Delirium, Delirium, Dementia, Amnestic, Cognitive Disorders, Delayed Emergence From Anesthesia, Cognitive Disorders
Interventions: Ramelteon, Microcrystalline Cellulose, Riboflavin 100 mg; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Activity-Related Knee Discomfort, Joint Discomfort, Functional Joint Pain, Functional Knee Pain, Knee Acute and Chronic Pain
Interventions: NT-II™ (240 mg), NT-II™ 480 mg, Glucosamine/Chondroitin; Dietary Supplement
Lead sponsor: Hofseth Biocare ASA; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Solid Tumors
Interventions: Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine, Inavolisib, Belvarafenib, Pralsetinib, Divarasib, Camonsertib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Not listed
Enrollment: 920 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 32
States / cities: Goodyear, Arizona • Los Angeles, California • Newport Beach, California + 25 more

Conditions: Huntington's Disease
Interventions: Pridopidine, Placebo; Drug · Other
Lead sponsor: Prilenia; Industry
Eligibility: 21 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 16
States / cities: La Jolla, California • Los Angeles, California • Englewood, Colorado + 12 more

Conditions: Psychiatric Disorders
Interventions: KarXT, KarX-EC; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 4
States / cities: Little Rock, Arkansas • Orange, California • Decatur, Georgia + 1 more

Conditions: Cortical Excitability, Psychiatric Disorder
Interventions: L-theanine, Placebo; Drug
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Recurrent Glioblastoma or Other Glioma Subtypes
Interventions: BGJ398; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 9
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 5 more

Conditions: Immune Thrombocytopenic Purpura
Interventions: Dexamethasone USP Micronized, Prednisone; Drug
Lead sponsor: Carelon Research; Other
Eligibility: 15 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 18
States / cities: New Orleans, Louisiana • Baltimore, Maryland • Boston, Massachusetts + 10 more

Conditions: Diabetes Mellitus
Interventions: BGP-15 100 mg QD, BGP-15 100 mg BID, Placebo BID, BGP-15 200 mg QD, BGP-15 200 mg BID, BGP-15 400 mg QD; Drug
Lead sponsor: N-Gene Research Laboratories, Inc.; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Los Angeles, California • Paramount, California • Tustin, California + 17 more

Conditions: Stroke
Interventions: Tocotrienol Capsules, Placebo Vehicle; Dietary Supplement · Other
Lead sponsor: Ohio State University; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Columbus, Ohio

Conditions: Cocaine Use
Interventions: l-tetrahydropalmatine (l-THP), Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Nephrectomy
Interventions: Acetaminophen, Placebos, Placebo Oral Tablet; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 89 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Major Depressive Disorder
Interventions: saredutant (SR48968), escitalopram, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Lymphoma, T-Cell, Cutaneous
Interventions: Quisinostat, 12 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 216
States / cities: Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 132 more

Conditions: Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI), FDC
Interventions: Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil, Esomeprazole, amoxicillin-clavulanate; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Urinary Tract Infections
Interventions: D-Mannose; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 20 Years and older · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Serotonin Selective Reuptake Inhibitor Treatment of Dual Diagnosis Post-traumatic Stress Disorder and Alcohol Problems

A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881

Essential Fatty Acids for Major Depression

ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZ

PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

Ramelteon in the Prevention of Post-operative Delirium

NT-II™ Collagen for Joint Discomfort and Function

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders

Effects of L-theanine on Motor Cortex Excitability in Healthy Subjects: A Paired-Pulse TMS Study

A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

Initial Treatment of Patients With Immune Thrombocytopenic Purpura

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Nutrition Blood Outcomes Following Tocotrienol N2B

L-tetrahydropalmatine (l-THP) Treatment for Cocaine Use Disorder

Efficacy of IV Acetaminophen Versus Oral Acetaminophen

An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder

A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

Nutraceutical Efficacy for rUTI